Description: Novacyt S.A., together with its subsidiaries, engages in developing, manufacturing, and commercializing clinical diagnostic products for cancer and infectious diseases in Africa, Europe, the Asia Pacific, the United States, and the Middle East. The company operates through Corporate and Diagnostics and Molecular Testing segments. The Corporate and Diagnostics segment manufactures and distributes reagents and kits for bacterial and blood tests. The Molecular Testing segment designs, manufactures and distributes test kits for certain diseases in humans, animals, and food products. The company's diagnostic products are used in oncology, microbiology, haematology, and serology testing. It also develops, manufactures, and distributes diagnostic products for food laboratories; and manufactures and supplies reagents, as well as tests for in vitro diagnostic tests and blood grouping application, under the Plasmatec and Biotec brand names. It serves universities, hospitals, clinics, and testing laboratories. The company was founded in 2006 and is based in Camberley, the United Kingdom.
Home Page: www.novacyt.com
13 Avenue Morane Saulnier
Vélizy-Villacoublay,
78140
France
Phone:
33 1 39 46 51 04
Officers
| Name | Title |
|---|---|
| Mr. James Martin McCarthy | CFO, Acting CEO, Company Sec. & Director |
| Bryan Close | Chief Operations Officer |
| Ms. Wendy Karban | Group HR Mang. |
| Mr. David Franks | Chief HR Officer |
| Paul Oladimeji | Group Head of R&D |
| Mr. Gérald Ulrich | Chief Exec. Officer of Bus. Devel. |
| Mr. Steve Gibson | Group Financial Controller |
Exchange: PINK
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.4043 |
| Price-to-Sales TTM: | 1.0367 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 210 |